XBiotech Inc
For the period ended Dec 31, 2023. Filed Mar 15, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 15, 2024
XBIT$1.91+1.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
| Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Net loss | $(24,557) | $(32,900) |
| Realized comprehensive income | - | (1,567) |
| Foreign currency translation adjustment | (252) | 422 |
| Reclassification of deferred tax assets | (574) | - |
| Comprehensive loss | $(25,383) | $(34,045) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.